Skip to main content
Internal Medicine logoLink to Internal Medicine
letter
. 2019 Apr 17;58(16):2419. doi: 10.2169/internalmedicine.2661-19

The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome

Takahiko Fukuchi 1, Hitoshi Sugawara 1
PMCID: PMC6746644  PMID: 30996192

To the Editor We read the interesting article, “Fatal neutropenic enterocolitis caused by Stenotrophomonas maltophilia: A rare and underrecognized entity,” by Kaito et al. in Internal Medicine (1). The patient's clinical course as described by the medical team reflects their persistent struggle to treat such a difficult disease and its complications. We appreciate their eager and fervent treatment of this patient. However, in patients receiving a high-dose corticosteroid, one tablet per day of prophylactic sulfamethoxazole-trimethoprim might help prevent diseases caused by typical pathogens in extremely immunosuppressed patients (2,3), as S. maltophilia is highly susceptible to this compound antibiotic (4).

Although this antibiotic has the adverse effect of bone marrow suppression and skin eruptions, which afflict treated patients simultaneously, the addition of this treatment might have enabled this patient to achieve a more favorable outcome. Alternatively, fluoroquinolones, which usually have efficacy against this pathogen (4), might have also been a viable option, although this antibiotic is typically administered for the first 100 days after stem cell transplantation (5).

We would like to ask the medical team whether they considered administering either sulfamethoxazole-trimethoprim or fluoroquinolones during the treatment course. The addition of such prophylactic antibiotics can help to achieve a favorable outcome in such cases.

The authors state that they have no Conflict of Interest (COI).

References

  • 1.Kaito S, Sekiya N, Najima Y, et al. Fatal neutropenic enterocolitis caused by Stenotrophomonas maltophilia: a rare and underrecognized entity. Intern Med 57: 3667-3671, 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 44: 1350-1363, 2014. [DOI] [PubMed] [Google Scholar]
  • 3.Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised Non-HIV-infected patients: systematic review and meta-analysis of randomized cotrolled trials. Mayo Clin Proc 82: 1052-1059, 2007. [DOI] [PubMed] [Google Scholar]
  • 4.Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9: 312-323, 2009. [DOI] [PubMed] [Google Scholar]
  • 5.Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15: 1143-1238, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Internal Medicine are provided here courtesy of Japanese Society of Internal Medicine

RESOURCES